Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2021-10-29 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial disclosure from Neuland Laboratories Limited dated October 29, 2021. It includes unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2021, along with limited review reports by statutory auditors. The document references compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and includes detailed financial tables, notes, and auditor's review statements. This matches the characteristics of an Interim / Quarterly Report (IR), as it contains substantive financial data and analysis for a period shorter than a full fiscal year (quarter and half year). It is not merely an announcement or certification but includes the actual financial results and auditor review. Therefore, the correct classification is IR (Interim / Quarterly Report).
2021-10-29 English
Press Release
Regulatory Filings
2021-10-29 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a detailed financial disclosure from Neuland Laboratories Limited dated October 29, 2021. It includes unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2021, along with limited review reports by statutory auditors. The document references compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and Indian Accounting Standards (Ind AS 34) for interim financial reporting. It contains comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, earnings per share, and assets and liabilities. The presence of unaudited quarterly and half-year financial results with substantive financial data and auditor review indicates this is an Interim / Quarterly Report. It is not merely an announcement or certification but contains actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2021-10-29 English
Updates
Major Shareholding Notification Classification · 95% confidence The document contains a table listing promoters or promoter groups seeking reclassification along with their equity shares held and percentage of shareholding. There is no indication of financial statements, management discussion, voting results, or other report types. The content relates to shareholding details and reclassification requests, which typically fall under regulatory announcements about shareholding or ownership structure changes. Given the absence of other report types and the focus on shareholding, the most appropriate classification is Major Shareholding Notification (MRQ). The document is short and factual, supporting this classification with high confidence.
2021-10-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Earnings Release Classification · 95% confidence The document is a notice addressed to stock exchanges about the upcoming earnings call and results release for the second quarter and half year ended September 30, 2021. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, which governs disclosure of material events. The document does not contain actual financial statements or detailed financial analysis but rather announces the date and time of the earnings call and the results release. The document length is short (2589 characters) and serves as an announcement rather than the earnings release itself or the call transcript. Therefore, it fits best under the category of Earnings Release (ER) as an initial announcement of quarterly financial results and earnings call details.
2021-10-25 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document text is extremely short (59 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any announcement text. Given the lack of information, the document cannot be classified as a report or announcement type. According to the rules, such minimal content defaults to Regulatory Filings (RNS) as a fallback category.
2021-10-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.